REUTERS: UnitedHealth Group Inc will stick with its decision to pass on drug maker discounts to patients to help them beat rising medicine prices despite the U.S. government having withdrawn a similar proposed policy in its health programs, its top executive said on Thursday.
"We think UnitedHealth is underperforming the peers today likely because on the call, they guided 2019 revenues to now be 'at or slightly below' the prior revenue guidance range of US$243-245 billion," Scott Fidel an analyst at Stephens said. Wichmann said the government's decision showed that the Trump administration values pharmacy benefit managers as a"counterbalance" to drug prices.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: